- Home
- ROIV vs CELH Comparison
ROIV vs CELH Comparison
Compare ROIV & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CELH
- Stock Information
- Founded
- ROIV 2014
- CELH 2004
- Country
- ROIV United Kingdom
- CELH United States
- Employees
- ROIV N/A
- CELH N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CELH Beverages (Production/Distribution)
- Sector
- ROIV Health Care
- CELH Consumer Staples
- Exchange
- ROIV Nasdaq
- CELH Nasdaq
- Market Cap
- ROIV 7.8B
- CELH 10.3B
- IPO Year
- ROIV N/A
- CELH N/A
- Fundamental
- Price
- ROIV $11.28
- CELH $46.82
- Analyst Decision
- ROIV Buy
- CELH Strong Buy
- Analyst Count
- ROIV 4
- CELH 17
- Target Price
- ROIV $17.50
- CELH $47.24
- AVG Volume (30 Days)
- ROIV 6.6M
- CELH 7.5M
- Earning Date
- ROIV 08-07-2025
- CELH 08-05-2025
- Dividend Yield
- ROIV N/A
- CELH N/A
- EPS Growth
- ROIV N/A
- CELH N/A
- EPS
- ROIV N/A
- CELH 0.32
- Revenue
- ROIV $29,053,000.00
- CELH $1,329,198,000.00
- Revenue This Year
- ROIV $2.64
- CELH $60.22
- Revenue Next Year
- ROIV $378.09
- CELH $25.97
- P/E Ratio
- ROIV N/A
- CELH $143.52
- Revenue Growth
- ROIV N/A
- CELH N/A
- 52 Week Low
- ROIV $8.73
- CELH $21.10
- 52 Week High
- ROIV $13.06
- CELH $61.25
- Technical
- Relative Strength Index (RSI)
- ROIV 53.61
- CELH 69.65
- Support Level
- ROIV $11.25
- CELH $42.24
- Resistance Level
- ROIV $11.82
- CELH $46.99
- Average True Range (ATR)
- ROIV 0.33
- CELH 1.58
- MACD
- ROIV -0.00
- CELH 0.24
- Stochastic Oscillator
- ROIV 52.97
- CELH 75.67
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 95% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), Celsius On-the-Go powder packets, and the recently acquired portfolio of Alani Nu energy drinks and snacks. Celsius dedicates its efforts to branding and innovation, while it largely utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.